RedHill Biopharma Ltd. RDHL
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
RedHill Biopharma Ltd. (RDHL) is a healthcare company listed in the US with a market value of about $3M. In fiscal year 2024 it had revenue of $8M and net income of -$8M, a net margin of -102.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 5% a year, a 5-year average ROIC of 77%.
About RedHill Biopharma
RedHill Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3000 in 2015 to $8M in 2024, growth of about 140.4% a year. It was profitable in 1 of the last 10 years in our data.
Score: 1.2 / 5
Checks passed
- Profit margin improving
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | — | $62M | $86M | $64M | $6M | $8M | $4M | $101000 | $3000 |
| Net income | -$8M | $24M | -$72M | -$98M | -$76M | -$42M | -$39M | -$46M | -$29M | -$21M |
| Free cash flow | -$9M | -$36M | -$29M | -$65M | -$49M | -$41M | -$34M | -$45M | -$28M | -$18M |
| EPS (diluted) | $-0.93 | $2.69 | $-8.06 | $-11.00 | $-8.57 | $-4.76 | $-4.37 | $-5.12 | $-3.30 | $-2.37 |
| Net margin | -102.8% | — | -116.0% | -114.0% | -118.4% | -672.5% | -464.4% | -1136.6% | -29079.2% | -703000.0% |
| ROIC | — | 482.3% | -50.7% | -69.3% | -52.8% | -56.9% | -60.7% | -91.1% | -38.5% | -28.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does RedHill Biopharma pay a dividend?
Not currently.
Is RedHill Biopharma a good stock to buy?
We do not give buy or sell advice. RedHill Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.